Treating fatty liver disease by modulating mitochondrial pyruvate metabolism

Hepatol Commun. 2017 Apr 18;1(3):193-197. doi: 10.1002/hep4.1036. eCollection 2017 May.

Abstract

Modifying the entry of pyruvate into mitochondria may provide a unique approach to treat metabolic disease. The pharmacology of a new class of insulin sensitizers directed against a newly identified mitochondrial target may treat many aspects of nonalcoholic steatohepatitis, including fibrosis. This commentary suggests treating nonalcoholic steatohepatitis through a newly identified mechanism consistent with pathophysiology. (Hepatology Communications 2017;1:193-197).